An interventional study of oZTEo in Inflammatory Arthritis, sponsored by Mayo Clinic. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 413 studies in Arthritis with a site in United States — 38 open to participants now, 55 under way, 4 of them phase 3. Arthritis · United States.
Among the 413 studies in Arthritis with a site in United States, this one is the 270th largest by enrollment of the 337 interventional ones that give a count, is one of 14 that started in 2024, is one of 148 with no phase, reaches primary completion later than 18 of the 51 other live ones, and was the 388th registered.
843 studies on the registry are indexed under Arthritis; 118 are open to participants now.
Browse Arthritis studies →38 of the 413 studies in Arthritis with a site in United States are open now. Recruiting first, the newest first:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Margaret L Gourlay, MD, MPH · Sites in United States
Ages 50–64
University of Chicago · Sites in United States
Ages 40+
Faith A. Richardson · Sites in United States
Ages 21–80 · Healthy volunteers
Terry L. Wahls · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 78 Arthritis studies recruiting now, 41 (53%) set no upper age limit and 20 (26%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
413 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 78 · Phase 3 73 · Phase 4 17
First in 1979; this study’s year is marked. 14 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 97 across 599 interventional studies indexed under Arthritis.
Median enrollment 100 across the 337 interventional studies, 134 across the 75 observational. Of the 317 that completed or were terminated, 142 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
186 of 413 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
Mayo Clinic has 3 studies filed under Arthritis — fewer than ten, so there is no comparison to draw.
16 of the studies in Arthritis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05658575Phase 3Olatec Therapeutics, Inc.Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | 2026-12-31 |
| NCT06550024CrannMedSakuraBead Used as Resorbable Embolic for Genicular Artery Embolization | 2026-12 |
| NCT06383585Mayo Clinic3D DL Ozteo in the Detection of Osseous Changes in Patients With Inflammatory Arthritis | 2026-12-10 |
| NCT05666167VA Office of Research and DevelopmentExpanding Exercise Programming for Veterans Through Telehealth | 2026-12-31 |
| NCT06915012First Institute of All MedicinesImpact of Biophoton Therapy on Chronic Severe Arthritis Pain | 2026-12-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 413 studies in Arthritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project intends to explore and validate the utility of new MRI pulse sequence, 3D DL oZTEo, in the detection of osseous erosions of the hand in patients with inflammatory arthritis. The detection of osseous structural changes, such as erosive disease, is routinely assessed in patients with rheumatic conditions such as rheumatoid arthritis, as it alters clinical management, and in some cases assists in diagnosis. Currently, this is most often assessed with radiography and conventional MRI.
This project intends to explore and validate the utility of new MRI pulse sequence, 3D DL oZTEo, in the detection of osseous erosions of the hand in patients with inflammatory arthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Less than18 years of age
All patients will have the FDA approved MRI pulse sequence, oZTEo, added to their already ordered standard of care MRI examination.
Device: oZTEo
An FDA approved MRI pulse sequence, oZTEo, will be added to a standard of care MRI examination. The oZTEo pulse sequence will be anonymized and sent to GE Healthcare for the application of a deep learning algorithm, 3D DL.
Also known as: 3D DL oZTEo
The binary (yes/no) presence of bony erosions as detected by hand MRI with and without the addition of the 3D DL oZTEo sequence.
The primary outcome
Time frame: 1 day
The number of erosions (continuous) as detected by hand MRI with and without the addition of the 3D DL oZTEo sequence.
The secondary outcome
Time frame: 1 day
Plan to share: No
Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.
Of 134 non-industry interventional studies with no phase under Arthritis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 24 months is below that.
Counting every sponsor, half of 167 studies reached it within 31 months; a quarter within 13 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.